No universally recognized classification criteria currently exist for discoid lupus erythematosus (DLE), which has led to problematic heterogeneity in observational and interventional clinical studies across the field. Continue reading
Chapel Hill Consensus Conference (CHCC) is a nomenclature system (nosology). It is neither a classification system that specifies what findings must be observed in a specific patient to classify that patient for clinical research nor a diagnostic system that directs clinical management. Continue reading
Vogt-Koyanagi-Harada disease (VKHD) is a bilateral, chronic granulomatous panuveitis associated with central nervous system, auditory, and integumentary manifestations. Continue reading
Assessment in SpondyloArthritis international Society (ASAS) criteria were validated in an international cohort trial with a sensibility and specificity close to 82.9 and 84.4%, respectively. Continue reading
Raynaud’s phenomenon (RP), is a disorder of the microvasculature that generally affects the fingers and toes but can present on other extremities such as the nose, ears and nipples. Continue reading
Antiphospholipid antibody syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis, complications during pregnancy, and the presence of antiphospholipid antibodies (APL) in plasma. Continue reading
Gout, which is characterized by deposition of monosodium urate monohydrate (MSU) in synovial fluid and other tissues, is the most common form of inflammatory arthritis. Continue reading
A diagnosis of primary Sjögren’s syndrome is often made on the basis of a classic triad of symptoms: dryness of the mouth and eyes, fatigue, and pain. Systemic complications, which are present in 30 to 40% of patients, may provide the first clues to the disease.
This simple clinical case definition of fibromyalgia correctly classifies 88.1% of cases classified by the ACR classification criteria, and does not require a physical or tender point examination. Continue reading
The diagnosis of familial Mediterranean fever (FMF) is based upon three factors: typical clinical manifestations, a positive response to colchicine therapy, and genetic testing, although currently available tests do not detect all mutations associated with FMF.